Rodec Pharma, a veterinary healthcare outfit, makes animal feed supplements & markets veterinary prescription meds. They are out to help livestock farmers & the likes - vets, distributors and animal hospitals - all over the country in India.
Founded way back in 1997, in Ghaziabad, Uttar Pradesh, Rodec Pharma used to be all about marketing but over the years it's built up into a proper animal healthcare company with a feed supplement factory of its own. Their portfolio has grown to 35 products across loads of different therapeutic and nutritional areas, with a whopping 29 different flavours/variations to boot.
They filed their Draft Red Herring Prospectus with SEBI back in January 2026, & have just got the thumbs up from SEBI after all that, so now the public issue is all set to go ahead.
Rodec Pharma IPO Details
Rodec Pharma IPO Dates - What We Know So Far
By June 2026, Rodec Pharma has still to make public the official dates when the IPO will open and close. If you're an investor, you'll want to keep an eye out for the Red Herring Prospectus (RHP) and any notifications from the stock exchange that will have the final details.
The Full Picture On Price Band and Lot Size
As of now, we don't have any information on just how much the shares are going to cost or what the minimum number of shares investors will be able to buy. The details on these points should become clearer as the IPO gets closer to launching and will be included in the RHP once its finalised.
Issue Size and Offer Structure
One of the key takeaways when it comes to the Rodec Pharma IPO is that it's an all-seller game where the 56.50 lakh equity shares are being put up for sale by promoter Mukesh Kumar Gupta. Since there isn't a new issue of shares part of this IPO, Rodec Pharma itself will receive no cash from it. All the cash will go to the seller. Mainly though, the IPO is about getting the company a stock exchange listing and giving existing shareholders some cash.
Rodec Pharma Products and Business Model
Rodec Pharma operates in the animal healthcare industry and focuses on products aimed at improving livestock health, productivity, and nutrition.
Its product portfolio includes:
- Veterinary antibiotics
- Anthelmintics
- Antispasmodics
- Analgesics and antipyretics
- Ectoparasiticides
- Animal feed supplements
- Nutritional formulations for livestock
The company markets products through a widespread distribution network covering Uttar Pradesh, Maharashtra, Haryana, Punjab, Gujarat, Rajasthan, Madhya Pradesh, Telangana, Bihar, Jharkhand, Assam, Uttarakhand, Himachal Pradesh, West Bengal and other states.
Rodec Pharma Financial Performance
Profit & Loss Statement in Crore.
The company has demonstrated strong earnings growth over the last three financial years.
- Revenue increased from ₹71.72 crore in FY23 to ₹108.19 crore in FY 25.
- Net profit increased from ₹5.21 crore to ₹18.26 crore during the same period.
- FY25 profit growth exceeded 65% year-on-year.
Balance Sheet Highlights in Crore.
These numbers speak to a business that is both profitable and in a good financial position - the kind of situation where you can earn a decent return on the money you have invested the company, and you're not taking on too much debt while doing it.
What Rodec Pharma does well?
A track record of business growth
Rodec Pharma has been posting steady revenue and profit increases over the last three years, and that's largely thanks to a growing demand for its products in the livestock healthcare market.
Financials that are hard to ignore
The numbers on profitability - RoNW at 36.49% and ROCE nudging 40% - show that the company is making the most of the money it's got, and that stacks up pretty well against its competitors.
A healthy animal health industry
The Indian animal health market looks set to keep on growing, thanks to a rising livestock population, people eating more dairy products, government efforts to prevent disease, and a growing awareness of the importance of animal nutrition.
A diverse range of products
The company works across two main areas - pharmaceuticals and animal nutrition - so if one area of business happens to slow down, there's still plenty of potential elsewhere for Rodec Pharma to make sales.
A strong network of suppliers and customers
Rodec Pharma has a presence in lots of different states, which gives it a big customer base and means it's well placed to expand into even more areas in the future.
Risks and Concerns - Things That Might Keep You Up at Night
Entire IPO is an OFS - Not Exactly a Cash Cow
Since the whole IPO is just an offer for sale, it basically means the company isn't getting any fresh capital to help it grow, cut debt or drive business forward. That's a pretty big drawback as far as the company's finances are concerned.
Lean on Third-Party Manufacturers
The fact that a lot of its veterinary pharmaceutical products come from third party manufacturers creates some pretty real operational and supply chain risks.
Down on Luck with Geography
Surprisingly, a lot of its revenue comes from Uttar Pradesh which could make it vulnerable to any regional specific market or regulatory ups and downs.
Not Long Enough in the Factory Game
Its in-house manufacturing only kicked off in December 2022, so right now investors don't have a lot to go on when it comes to judging the company's manufacturing performance over time.
Not the Research & Development Star You Might Think
To be honest - the company doesn't really do that much in-house R&D - which might hold it back long term in a pretty fast moving pharmaceutical market.
Expert Review and Verdict
From the very start, Rodec Pharma Limited looks like a business with a solid foundation , running a business model that's well set up to thrive in a pretty defensive and extremely high-demand sector. For India's massive rural economy, livestock health and dairy optimisation are just two costs of doing business that people can't really avoid - and that gives the company some good protection from all the ups and downs of the wider economy.
The Verdict
The success or otherwise of this public listing will all come down to how the company is valued in the end. Because it's an OFS (which is a pretty aggressive way to get listed, to be honest), if they price it too high at the start then it's likely that investors who get in at the beginning won't make a lot of money by the time the market has settled down. So, anyone looking to invest should probably just wait to see the RHP filing and then take a good hard look at the price band they're offering against the company's actual earnings per share (EPS) - and do that over their actual annual earnings , rather than just estimates. If the company gets a fair price in the end - and that's relative to some of the bigger players in the animal health space - then they've got a great track record to show for it, and that's definitely worth considering for long-term investors looking to keep some money in the market.
